Clinical implications of antibiotic impact on gastrointestinal microbiota and Clostridium difficile infection

被引:37
作者
Khanna, Sahil [1 ]
Pardi, Darrell S. [1 ]
机构
[1] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA
关键词
Clostridium difficile infection; microbiota; microbiome; antibiotics; stewardship; antibiotic-associated diarrhea; Clostridium difficile associated diarrhea; VANCOMYCIN-RESISTANT ENTEROCOCCI; CLINDAMYCIN-ASSOCIATED COLITIS; LONG-TERM PERSISTENCE; HUMAN GUT MICROBIOTA; FECAL MICROBIOTA; INTESTINAL MICROBIOTA; ORAL METRONIDAZOLE; EPIDEMIOLOGY; HOST; FIDAXOMICIN;
D O I
10.1586/17474124.2016.1158097
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The human gastrointestinal (GI) microbiota plays an important role in human health. Anaerobic bacteria prevalent in the normal colon suppress the growth of non-commensal microorganisms, thus maintaining colonic homeostasis. The GI microbiota is influenced by both patient-specific and environmental factors, particularly antibiotics. Antibiotics can alter the native GI microbiota composition, leading to decreased colonization resistance and opportunistic proliferation of non-native organisms. A common and potentially serious antibiotic-induced sequela associated with GI microbiota imbalance is Clostridium difficile infection (CDI), which may become recurrent if dysbiosis persists. This review focuses on the association between antibiotics and CDI, and the antibiotic-induced disruption leading to recurrent CDI. Promoting antibiotic stewardship is pivotal in protecting native microbiota and reducing the incidence of CDI and other GI infections.
引用
收藏
页码:1145 / 1152
页数:8
相关论文
共 93 条
  • [1] Defining the Vulnerable Period for Re-Establishment of Clostridium difficile Colonization after Treatment of C. difficile Infection with Oral Vancomycin or Metronidazole
    Abujamel, Turki
    Cadnum, Jennifer L.
    Jury, Lucy A.
    Sunkesula, Venkata C. K.
    Kundrapu, Sirisha
    Jump, Robin L.
    Stintzi, Alain C.
    Donskey, Curtis J.
    [J]. PLOS ONE, 2013, 8 (10):
  • [2] Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease
    Al-Nassir, Wafa N.
    Sethi, Ajay K.
    Li, Yuejin
    Pultz, Michael J.
    Riggs, Michelle M.
    Donskey, Curtis J.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (07) : 2403 - 2406
  • [3] Barbut F, 2000, J CLIN MICROBIOL, V38, P2386
  • [4] ANTIBIOTIC-ASSOCIATED PSEUDOMEMBRANOUS COLITIS DUE TO TOXIN-PRODUCING CLOSTRIDIA
    BARTLETT, JG
    CHANG, TW
    GURWITH, M
    GORBACH, SL
    ONDERDONK, AB
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1978, 298 (10) : 531 - 534
  • [5] Clinical recognition and diagnosis of Clostridium difficile infection
    Bartlett, John G.
    Gerding, Dale N.
    [J]. CLINICAL INFECTIOUS DISEASES, 2008, 46 : S12 - S18
  • [6] Individuality in gut microbiota composition is a complex polygenic trait shaped by multiple environmental and host genetic factors
    Benson, Andrew K.
    Kelly, Scott A.
    Legge, Ryan
    Ma, Fangrui
    Low, Soo Jen
    Kim, Jaehyoung
    Zhang, Min
    Oh, Phaik Lyn
    Nehrenberg, Derrick
    Hua, Kunjie
    Kachman, Stephen D.
    Moriyama, Etsuko N.
    Walter, Jens
    Peterson, Daniel A.
    Pomp, Daniel
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (44) : 18933 - 18938
  • [7] Risk factors for Clostridium difficile infection
    Bignardi, GE
    [J]. JOURNAL OF HOSPITAL INFECTION, 1998, 40 (01) : 1 - 15
  • [8] 'Gut health': a new objective in medicine?
    Bischoff, Stephan C.
    [J]. BMC MEDICINE, 2011, 9
  • [9] Stop the killing of beneficial bacteria
    Blaser, Martin
    [J]. NATURE, 2011, 476 (7361) : 393 - 394
  • [10] Time to include the gut microbiota in the hygienic standardisation of laboratory rodents
    Bleich, Andre
    Hansen, Axel Kornerup
    [J]. COMPARATIVE IMMUNOLOGY MICROBIOLOGY AND INFECTIOUS DISEASES, 2012, 35 (02) : 81 - 92